14 results about "Blood pressure increase" patented technology

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.

The invention relates to an application of a traditional Chinese medicine composition in preparation of a medicine for treating hypertension, which is characterized in that the traditional Chinese medicine composition is prepared from gypsum, rehmannia, ophiopogon root, rhizoma anemarrhenae and achyranthes root. The composition disclosed by the invention can be used for remarkably reducing systolic pressure of spontaneously hypertensive rats and reducing blood pressure rise of the rats caused by feeding of high-fat feed, so that the traditional Chinese medicine composition has a relatively good treatment effect on hypertension.

The invention discloses application of 9 '''-salvianolic acid B monomethyl ester in preparation of a medicine for preventing and / or treating atrial fibrillation, and belongs to the technical field of biological medicine. Experiments prove that the 9 ''-MSB disclosed by the invention can be used for remarkably improving the blood pressure rise and the atrial inner diameter increase of a mouse after Ang II perfusion; the increase of the occurrence rate and the duration time of atrial fibrillation is inhibited; macrophage infiltration, collagen deposition and oxidative stress injury of atrial tissues are reduced, and the protective effect of 9 ''-MSB is obviously superior to that of SalB. Therefore, the 9 ''-MSB can be used for preparing the medicine for preventing and / or treating the atrial fibrillation, and the invention proves that the 9''-MSB can be used as a new medicine for adjuvant treatment of the atrial fibrillation and has important clinical guiding significance.

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.

The invention discloses targeted prebiotic plant extraction dietary powder for conditioning hypertension and a preparation method thereof. According to the present invention, the lactobacillus plantarum CECT5716, the bifidobacterium lactis BLa80 and other strains selected in the formula can regulate the renin-angiotensin system balance by inhibiting the activity of the angiotensin converting enzyme so as to reduce the vasosystolic pressure from the neuroendocrine level; hawthorn flavone and pueraria isoflavone directly act on blood vessels to expand peripheral arteries, improve coronary artery blood flow and enhance blood vessel elasticity; the gamma-aminobutyric acid serving as a neurotransmitter can relieve sympathetic nerve hyperexcitation and reduce blood pressure fluctuation caused by emotion or pressure. Meanwhile, prebiotics such as resistant dextrin provide nutrients for probiotics, promote generation of intestinal short-chain fatty acids, activate a vascular endothelium protection pathway through an intestinal-metabolic axis, form a triple antihypertensive network of strain regulation, plant intervention and flora synergy, and cover different pathological links of blood pressure rise.

The present application provides a method for assessing the risk of blood pressure during pregnancy, an electronic device, and a readable storage medium, and relates to the field of terminal technology. The method is applied to electronic devices, including: obtaining the prediction results of the blood circulation status, mental health status, and blood pressure fluctuation status of the next pregnancy cycle in the current pregnancy cycle; determining the risk assessment score of the blood pressure in the next pregnancy cycle based on the prediction results of the blood circulation status, mental health status, and blood pressure fluctuation status; when the risk assessment score is in the first interval, determining the blood pressure in the next pregnancy cycle as a risk-free level; when the risk assessment score is in the second interval, determining the blood pressure in the next pregnancy cycle as a risky level. Based on the above technical solution, the electronic device can predict and assess the blood pressure risk level of the next pregnancy cycle in the current pregnancy cycle, and can remind the user to seek medical treatment in time when there is a risk, which helps the user pay attention to their own health and prevent high blood pressure during pregnancy.

To provide a useful blood pressure elevation suppressant. [Solution] A blood pressure elevation inhibitor containing as an active ingredient one or more compounds selected from the group consisting of saclipin A (a compound represented by the following formula (2)), saclipin B, and derivatives thereof, isolated from an extract of Suizenji Nori. TIFF2026115124000007.tif68169

The invention relates to the technical field of biology, in particular to a blood biomarker, a kit and a medicine for regulating and controlling the blood pressure of old people. The blood biomarker is characterized by being at least one of the following non-coding RNA (Ribonucleic Acid) or proteins: LncRNA GAS5, miR-223-3p, NLRP3 and GSDMD. Compared with healthy old people, the expression of LncRNA GAS5 and NLRP3 in blood of old people with hypertension is increased, and the expression of miR-223-3p is reduced. The GSDMD participates in the blood pressure rise of the old mice caused by PM2.5. Therefore, the LncRNA GAS5, the miR-223-3p, the NLRP3 and the GSDMD in the blood of the senile hypertension patients have potential values as the senile hypertension diagnosis biomarkers and the intervention targets.

The invention discloses an application of Irisin autocrine probiotics in preparation of a medicine for preventing / treating salt-sensitive hypertension. According to the application disclosed by the invention, it is found for the first time that the probiotic B.Subtills-WB600-Irisin capable of automatically secreting Irisin protein simultaneously has the effects of preventing and treating salt-sensitive hypertension, can effectively inhibit the increase of systolic pressure and diastolic pressure induced by rats fed with high-salt diet, and can maintain the systolic pressure and diastolic pressure at a basic blood pressure level; in a Dahl-S rat model, the autotaxis Irisin probiotic treatment can improve the urine sodium excretion, so that the blood pressure rise induced by high-salt diet reverses 26 + / -8 mmHg (plt; 0.001). Compared with the traditional probiotics, the invention solves the key problems of protein stability, targeting and multi-mechanism synergy through a synthetic biological strategy, and can be used as a medicine for preventing and treating hypertension and related diseases thereof.

The present invention provides a composition containing, as an active ingredient, a ginseng extract selected from the group consisting of ginseng extract, red ginseng extract, and black ginseng extract. When the composition according to the present invention is administered in combination with a steroid drug, it has the effect of improving or suppressing side effects caused by the steroid drug, such as weakened immunity and increased risk of infection, steroid-induced diabetes, osteoporosis, increased blood pressure and electrolyte abnormalities, changes in body shape, myopathy, osteonecrosis, cataracts, skin changes, and behavioral disorders.

The invention discloses a blood pressure control method and device based on UWB imaging monitoring, and the method comprises the steps: detecting an activity intensity grade through obtaining a UWB imaging signal of a patient, generating a time-sharing energy storage signal, and storing quick release pressure and slow release pressure respectively; a spiral air bag layout is constructed in combination with the abdomen form of a patient to form a continuous pressure channel; establishing a mapping relation between the main control section and the supplementary section by adopting odd-even section alternate identification; a delay interval release sequence is generated based on getting-up preparation action detection, and quick release pressure is charged into the main control section in a delayed mode section by section to form interval pressure distribution; identifying the position of the pressure vacancy area, executing reverse air exhaust operation to generate an enhanced negative pressure field, and performing superimposed monitoring on the enhanced negative pressure field and the blood flow siphon driving force to obtain negative pressure regulation and control parameters; slowly-released pressure released to the supplement section and dynamic interval pressure are distributed and superposed to form a complete spiral pressure field; pressure waves are driven to spirally ascend through the coupling effect of a spiral pressure field and an enhanced negative pressure field, blood pressure increasing data are monitored for dynamic optimization, and self-adaptive blood pressure control is achieved.

The invention relates to application of ITSA1 in preparation of a medicine for treating or preventing cardiac remodeling or hypertension, and belongs to the technical field of prevention of cardiovascular diseases. The method comprises the following steps: constructing a chronic intermittent hypoxia (CIH) animal model by using a mouse, performing blood pressure measurement 2 weeks, 4 weeks and 8 weeks before and during construction of the animal model, and performing cardiac ultrasound, Masson staining, alpha-SMA immunohistochemistry, WGA staining and the like after the model is finished. Experimental results show that the ITSA1 relieves blood pressure rise, accelerated heart rate, cardiac function, myocardial fibrosis and myocardial cell hypertrophy caused by chronic intermittent hypoxia. Experiments prove that the ITSA1 can effectively relieve blood pressure rise and cardiac remodeling caused by chronic intermittent hypoxia, and a foundation is laid for widening the clinical application range of the ITSA1.

According to one embodiment, a blood pressure measuring apparatus includes a blood pressure measurement unit, a warning estimator, and a signal output unit. The measurement unit measures blood pressure of a target person. The estimator monitors variation of blood pressure measured by the measurement unit and estimates the variation of the blood pressure as a sign of a blood pressure increase associated with an onset of sleep apnea syndrome if the blood pressure continuously decreases to a preset threshold or lower for a predetermined time or longer. The output unit outputs a sign notification signal to outside of the apparatus if the sign is estimated by the estimator.

The present application relates to the field of medical data information processing technology, and specifically to a method, system and storage medium for monitoring hypertension by combining traditional Chinese and Western medicine. The method comprises: collecting systolic pressure, diastolic pressure and heart rate of the monitored object at each moment of each day during the blood pressure monitoring cycle; determining the blood pressure increase amplitude and heart rate active reflection degree at each moment of each day; determining the behavioral activity at each moment of each day; obtaining the degree of blood pressure increase performance at each moment of each day; determining the cycle significance and systolic pressure performance excellence at each moment of each day; correspondingly, obtaining the diastolic pressure performance excellence at each moment of each day, and obtaining the comprehensive blood pressure excellence of each day; determining the blood pressure correlation degree of each day, and obtaining the correlation excellence of each day; obtaining the hypertension warning value of the monitored object, and performing hypertension monitoring on the monitored object. Thus, the accuracy of blood pressure data processing and monitoring is improved.